

Results of 2022 Annual General Meeting

3 November 2022

In accordance with Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), we advise details of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

—ENDS—

Authorised by Melanie Leydin, Company Secretary.

Contacts

Corporate

Melanie Leydin
Company Secretary
companysecretary@4DMedical.com

Media

Julia Maguire
+61 2 8999 3699
julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), the first modality to dynamically quantify ventilation throughout the lungs.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.

ANNUAL GENERAL MEETING
Thursday, 3 November, 2022

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

| Resolution Voted on at the meeting | | | Proxy Votes (as at proxy close) | | | | Total votes cast in the poll (where applicable) | | | |
|------------------------------------|---|------------------|---------------------------------|---------------------|-------------------------------|-----------|---|---------------------|------------|---------|
| No | Short Description | Strike Y/N/NA | For | Against | Discretionary (open votes) | Abstain | For | Against | Abstain ** | Result |
| 2 | REMUNERATION REPORT | N | 23,384,939 89.78% | 330,909 1.27% | 2,331,924 8.95% | 6,026,278 | 29,217,181 98.88% | 330,909 1.12% | 6,044,033 | Carried |
| 3 | ELECTION OF DIRECTOR MS EVONNE COLLIER | NA | 30,070,737 92.38% | 145,293 0.45% | 2,333,666 7.17% | 33,992 | 101,495,513 99.86% | 145,293 0.14% | 51,747 | Carried |
| 4 | RE-ELECTION OF DIRECTOR MR JOHN LIVINGSTON | NA | 21,966,271 67.58% | 8,208,986 25.26% | 2,328,086 7.16% | 80,345 | 93,368,145 91.90% | 8,226,308 8.10% | 98,100 | Carried |
| 5 | RE-ELECTION OF DIRECTOR MR JULIAN SUTTON | NA | 30,004,408 92.30% | 171,899 0.53% | 2,330,086 7.17% | 77,295 | 100,944,804 99.83% | 171,899 0.17% | 575,850 | Carried |
| 6 | GRANT OF OPTIONS TO THE MANAGING DIRECTOR AND CEO | NA | 23,330,090 73.37% | 6,132,321 19.29% | 2,334,953 7.34% | 786,324 | 29,165,361 82.63% | 6,132,321 17.37% | 804,079 | Carried |
| 7 | RENEWAL OF THE PROPORTIONAL TAKEOVER APPROVAL PROVISIONS IN THE CONSTITUTION OF COMPANY | NA | 27,471,821 91.27% | 276,811 0.92% | 2,351,057 7.81% | 2,483,999 | 98,913,988 99.72% | 276,811 0.28% | 2,501,754 | Carried |
| 8 | APPROVAL OF 10% PLACEMENT CAPACITY | NA | 18,443,258 61.25% | 9,325,340 30.97% | 2,344,574 7.79% | 2,470,516 | 89,875,192 90.58% | 9,343,095 9.42% | 2,474,266 | Carried |

** - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item